Personalized Cancer Treatment - Direct by Syndicate Bio

Somatic Cancer Panels

Personalized Cancer Treatment Through Genetic Profiling

A New Era in Cancer Care.

Every cancer is unique. Whether it’s prostate, breast, lung, liver, ovarian, or pancreatic cancer, the best outcomes come from understanding the genetic drivers behind each tumor.

At Direct by Syndicate Bio, we use advanced genomic profiling to uncover the mutations fueling cancer growth. This transforms care—moving beyond one-size-fits-all approaches to deliver actionable insights and targeted therapies tailored to each patient.

Why Genetic Profiling Matters in Cancer Treatment

This approach is reshaping how we treat cancers of the prostate, breast, lung, liver, ovary, and pancreas, as well as myeloid cancers—helping patients access therapies that are more effective and less toxic.

Our Genomic Tests: OncoMap50 & OncoMap90

We offer two powerful genomic profiling panels designed for different clinical needs:

Therapeutic Implications Across Cancer Types

Genetic profiling can reveal mutations that open the door to life-changing therapies, such as:

Prostate cancer treatment

Androgen receptor–targeted therapies guided by AR-V7 or DNA repair mutations.

Breast cancer treatment

HER2-directed therapies or PARP inhibitors for BRCA1/2 mutations.

Lung cancer treatment

EGFR, ALK, and KRAS G12C inhibitors for targeted precision therapy.

Liver cancer treatment

Biomarker-driven immunotherapy for MSI-High or PD-L1 positive tumors.

Ovarian cancer treatment

PARP inhibitors for BRCA mutations and HRD-positive tumors.

Pancreatic cancer treatment

Targeted therapy for KRAS, BRCA, or mismatch repair deficiencies.

Myeloid cancers (AML, MDS, etc.)

FLT3, IDH1/2, and NPM1 mutations guiding targeted inhibitors; TP53 and complex karyotype markers informing prognosis and treatment intensity.

Designed for Africa, Built for Impact

Direct by Syndicate Bio is committed to making cutting-edge genomic testing accessible across Africa. By integrating OncoMap50 for solid tumors and OncoMap90 for myeloid cancers into cancer care, we empower both patients and healthcare professionals to make smarter, faster, and more effective treatment decisions.

Frequently Asked Questions

What is genetic profiling of cancer?

Genetic profiling is a test that looks at the DNA of a tumor or blood cancer to identify mutations that may be driving its growth. These insights help doctors choose treatments that specifically target those mutations.

How does genetic profiling improve cancer treatment?

By understanding the genetic makeup of a tumor or blood cancer, doctors can recommend therapies that are more likely to work—such as targeted drugs or immunotherapies—rather than relying only on standard chemotherapy.

Which cancers benefit from genetic profiling?

Genomic testing is valuable across many cancers, including prostate, breast, lung, liver, ovarian, pancreatic cancers, and myeloid cancers like AML and MDS.

What’s the difference between OncoMap50 and OncoMap90?

OncoMap50 analyzes 50 key genes in solid tumors and is ideal for patients starting targeted therapy.

OncoMap90 covers 90 genes relevant to myeloid cancers, offering a comprehensive view for blood cancers such as AML and MDS.

Can genetic profiling help if standard treatments have failed?

Yes. Many patients who don’t respond to standard therapies discover new treatment options or clinical trials through genetic profiling.

Is this test available across Africa?

Yes. Direct by Syndicate Bio is dedicated to making precision oncology accessible across Africa, ensuring patients and healthcare providers can benefit from world-class genomic insights.

Take the Next Step

Because every cancer is different, treatment should be too.

For Patients & Families

Ask your doctor if OncoMap50 (solid tumors) or OncoMap90 (myeloid cancers) can guide your cancer treatment.

Hereditary Conditions Test

NIPT (Non-Invasive Prenatal Test) Gender

NIPT (Non-Invasive Prenatal Test) Basic

NIPT (Non-Invasive Prenatal Test) Standard

NIPT (Non-Invasive Prenatal Test) Plus

Comprehensive Hereditary Cancer Test (~300 genes)

Hereditary Breast and Ovarian Cancer Test (50 genes)

Hereditary Prostate Cancer Test (23 genes)

Hereditary Pancreatic Cancer Test (32 genes)

Hereditary Colorectal Cancer Test (44 genes)

OncoMap130 (130 genes)

OncoMap90 (90 genes)

Pharmacogenomics Test

Health & Wellness Test (80+ genes)